Irritable Bowel Syndrome Market 2018 by Key Players, Industry Trend, Size, growth and Forecasts
The Irritable Bowel Syndrome Market report provides complete detailed analysis of worldwide markets for Irritable Bowel Syndrome from 2018 and provides extensive market analysis by Assessment .Get more Illustration And market research by key players, region/country, share, revenue, sales, price, opportunities and size band.
Pune, India – May 10, 2018 /MarketersMedia/ —
Latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome Pipeline Market Review, H1 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.
Grab Discount on Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1499028
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 6, 1, 8 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Buy Corporate Copy of this Report at http://www.reportsnreports.com/purchase.aspx?name=1499028
Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
• The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
Reasons to buy
• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables & List of Figures
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome – Overview 10
Irritable Bowel Syndrome – Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 18
Irritable Bowel Syndrome – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Irritable Bowel Syndrome – Companies Involved in Therapeutics Development 26
4D Pharma PLC 26
Allergan Plc 26
Ardelyx Inc 26
ConSynance Therapeutics Inc 27
Cosmo Pharmaceuticals NV 27
Dong-A ST Co Ltd 28
Eisai Co Ltd 28
Enterome Bioscience SA 29
Contact Info:
Name: hrishkesh Patwardhan
Email: sales@reportsandreports.com
Organization: ReportsandReports
Address: Corporate Headquarters 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001.
Phone: + 1 888 391 5441
For more information, please visit http://www.reportsnreports.com
Source: MarketersMedia
Release ID: 343839
Copyright © 1999-2013 SproutNews.com
